Inclusion Criteria:  Age older than 18 yearsAge older than 18 years Signed informed consent form Stable angina pectoris (CCS I-III FC) with signs of myocardial ischemia despite treatment with antianginal drug(s) present either clinically and/ or at stress ECHO test with dobutamine History of myocardial infraction occurred 6 months and more from the inclusion date Trimetazidine (TMZ) is recommended as add on to the current antianginal treatment and this recommendation precedes inclusion of a patient in the study Intention to perform a stress echo with spackle tracking precedes the start of TMZ Physician's intention to perform a stress ECHO test within a 6-month period after the date of inclusion in the study  Exclusion Criteria:  Age over 75 years or under 18 years old Hypersensitivity to the active substance or any excipient specified in SmPc of TMZ 80 mg OD Parkinson's disease, parkinsonism symptoms, tremors, restless legs syndrome and other accompanying movement disorders Known severe or moderate renal impairment (creatinine clearance <60 ml / min). Angina pectoris of IV functional CCS class Heart failure IV functional class by NYHA Cardiac valves insufficiency with regurgitation of stage III and higher Myocardial infarction less than 6 months from the inclusion date Acute cerebrovascular event (stroke of various origins, transient ischemic attack) within 6 months before screening date Uncontrolled arterial hypertension of stage 3 (blood pressure above 180/100 mm Hg) despite ongoing antihypertensive therapy Fructose / sucrose intolerance, presence of glucose-galactose malabsorption syndrome, sucrose-somaltase deficiency and other enzymopathies associated with intolerance to sucrose, which is part of the drug Pregnancy, breastfeeding Any contraindications to stress echocardiography with dobutamine